Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Cited by (1,010)

Items 801–900 of 1,010

1. Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology.
   Herrmann, Sandra M., Abudayyeh, Ala, Gupta, Shruti, Gudsoorkar, Prakash, Klomjit, Nattawat, Motwani, Shveta S., Karam, Sabine, Costa E Silva, Verônica T., Khalid, Sheikh B., Anand, Shuchi et al. · 2025 · Kidney international
2. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer
   Luyao Wang, Qingxia Ma, Ruixue Yao, Jia Liu · 2019 · International Immunopharmacology
3. PRKDC : new biomarker and drug target for checkpoint blockade immunotherapy
   Kien Thiam Tan, Chun‐Nan Yeh, Yu‐Chan Chang, Jen-Hao Cheng, Wen‐Liang Fang, Yi‐Chen Yeh, Yu‐Chao Wang, Dennis Shin‐Shian Hsu, Chiao‐En Wu, Jiun‐I Lai et al. · 2020 · Journal for ImmunoTherapy of Cancer
4. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
   Shuo Xu, Ruixue Lai, Qian Zhao, Pandong Zhao, Ruili Zhao, Zhanjun Guo · 2021 · Frontiers in Immunology
5. Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments
   Tycho de Bakker, Fabrice Journé, Géraldine Descamps, Sven Saussez, Tatiana Dragan, Ghanem Ghanem, Mohammad Krayem, Dirk Van Gestel · 2022 · Frontiers in Oncology
6. Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
   Ana Belén Griso-Acevedo, Lucía Acero-Riaguas, Beatriz Castelo, José Luis Cebrián Carretero, Ana Sastre-Perona · 2022 · Cells
7. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
   Shayista Akbar, Afsheen Raza, Reyad Mohsin, Aladdin Kanbour, Shahnaz Majid Qadri, Aijaz Parray, Abdul Rehman Zar Gul, Anite Philip, Suma Vijayakumar, Maysaloun Merhi et al. · 2023 · Frontiers in Immunology
8. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
   Kai Wang, Lin Gui, Haizhen Lu, Xiaohui He, Dezhi Li, Chang Liu, Shaoyan Liu, Xiaolei Wang · 2023 · Frontiers in Immunology
9. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
   Talal El Zarif, Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha, Scot Anthony Niglio, Nicholas I. Simon, Andrew Warren Hahn, Curtis Alvin Pettaway et al. · 2023 · JNCI Journal of the National Cancer Institute
10. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions
    Kartik Mandal, Ganesh Kumar Barik, Manas Kumar Santra · 2025 · Molecular Cancer
11. Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway
    Yingnan Wang, Xing Qin, Xueqin Zhu, Wanjun Chen, Jianjun Zhang, Wantao Chen · 2017 · Oral Oncology
12. Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care
    O. Ben-Aharon, R. Magnezi, M. Leshno, D. Goldstein · 2017 · JAMA Oncology
13. Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer
    Ryuji Yasumatsu, Takahiro Wakasaki, Kazuki Hashimoto, Koichiro Nakashima, Tomomi Manako, Masahiko Taura, Mioko Matsuo, Takashi Nakagawa · 2019 · Head & Neck
14. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
    Daniel L. Faden, Fei Ding, Yan Lin, Shuyan Zhai, Fengshen Kuo, Timothy An-thy Chan, Luc G.T. Morris, Robert Louis Ferris · 2019 · Oral Oncology
15. An update: emerging drugs to treat squamous cell carcinomas of the head and neck
    Yoon Se Lee, Daniel E. Johnson, Jennifer Rubin Grandis · 2018 · Expert Opinion on Emerging Drugs
16. Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience
    Thomas Held, Paul Y. Windisch, Sati Akbaba, Kristin Lang, Rami Ateyah El Shafie, Denise Bernhardt, Peter K. Plinkert, Steffen Kargus, Stefan Rieken, Klaus K Herfarth et al. · 2019 · International Journal of Radiation Oncology*Biology*Physics
17. Regulation of Oncogenic Targets by miR-99a-3p (Passenger Strand of miR-99a-Duplex) in Head and Neck Squamous Cell Carcinoma
    Reona Okada, Keiichi Koshizuka, Yasutaka Yamada, Shogo Moriya, Naoko Kikkawa, Takashi Kinoshita, Toyoyuki Hanazawa, Naohiko Seki · 2019 · Cells
18. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
    Elena Goleva, Taras A. Lyubchenko, Lukas Kraehenbuehl, Mario E. Lacouture, Donald Y.M. Leung, Jeffrey A. Kern · 2021 · Annals of Allergy Asthma & Immunology
19. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects
    Ratna Veeramachaneni, Wangjie Yu, Jared M. Newton, Jan Ole Kemnade, Heath Devin Skinner, Andrew Gregory Sikora, Vlad Constantin Sandulache · 2021 · Journal for ImmunoTherapy of Cancer
20. T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
    Lucia Mazzotti, Anna Gaimari, Sara Bravaccini, Roberta Maltoni, Claudio Cerchione, Manel Juan, Europa Azucena González‐Navarro, Anna Pasetto, Daniela Nascimento Silva, Valentina Ancarani et al. · 2022 · International Journal of Molecular Sciences
21. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma
    Abrahim Al‐Mamgani, Mischa de Ridder, Arash Navran, W. Martin C. Klop, Jan Paul de Boer, Margot E. T. Tesselaar · 2017 · European Archives of Oto-Rhino-Laryngology
22. Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
    Alessandra Chen, Nabilah Ali, Peter D. Boasberg, Allen S. Ho · 2018 · Journal of Clinical Medicine
23. Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)
    Paulina Kozakiewicz, Ludmiła Grzybowska‐Szatkowska · 2018 · Oncology Letters
24. IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors
    Hyungseok Seo, Byung Seok Kim, Eun‐Ah Bae, Byung Soh Min, Yoon Dae Han, Sang Joon Shin, Chang‐Yuil Kang · 2018 · Cancer Immunology Research
25. Precision Therapy of Head and Neck Squamous Cell Carcinoma
    Peter J. Polverini, Nisha J. D’Silva, Yu L. Lei · 2018 · Journal of Dental Research
26. Immune check-point in cervical cancer
    Francesca De Felice, Cláudia Marchetti, Innocenza Palaia, R Ostuni, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici · 2018 · Critical Reviews in Oncology/Hematology
27. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
    Stephen M. F. Jamieson, Peter Tsai, Maria K. Kondratyev, Pratha Budhani, Arthur J. Liu, Neil N. Senzer, Elena Gabriela Chiorean, Shadia Ibrahim Jalal, John J. Nemunaitis, Dennis Kee et al. · 2018 · JCI Insight
28. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function
    Paul E. Clavijo, J. Friedman, Y. Robbins, E. Moore, E. Smith, M. Zauderer, E. Evans, C. Allen · 2018 · Cancer immunology research
29. Immunotherapeutic approaches in nasopharyngeal carcinoma
    James CH Chow, Roger KC Ngan, KM Cheung, William Chi Shing Cho · 2019 · Expert Opinion on Biological Therapy
30. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment
    Julie Lang, Anna Capasso, Kimberly Rae Jordan, Jena D. French, Adwitiya Kar, Stacey M. Bagby, Jacob Barbee, Betelehem W. Yacob, Lia Head, Kenneth D. Tompkins et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
31. Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review
    Julien Pierrard, Emmanuel Seront · 2019 · Current Oncology
32. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
    Juan Ruiz Bañobre, Ajay Goel · 2018 · Gastroenterology
33. CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression
    Joseph A. Westrich, Daniel W. Vermeer, Alexa Silva, Stephanie K. Bonney, Jennifer Berger, Louis Cicchini, Robert O. Greer, John I. Song, David Raben, Jill E. Slansky et al. · 2019 · Oncogene
34. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
    Rachel Galot, Christophe Le Tourneau, Esma Saâda-Bouzid, Amaury Daste, Caroline Even, Philip R. Debruyne, Stéphanie Henry, Sylvie Zanetta, A. Rutten, Lisa Francesca Licitra et al. · 2021 · European Journal of Cancer
35. MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
    Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan, Avital Beeri Shnerb, Sooraj Mathukkada, Jebrane Bouaoud, Lucas Michon, Ofra Novoplansky, Mai Badarni, Limor Cohen et al. · 2022 · Journal for ImmunoTherapy of Cancer
36. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events
    Muhammad Zain Farooq, Sheeba Ba Aqeel, Prasanth Lingamaneni, Rayli Pichardo, Aleeza Jawed, Saad Khalid, Shristi Upadhyay Banskota, Pingfu Fu, Ankit Mangla · 2022 · JAMA Network Open
37. Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
    Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng, Shibing Wang · 2023 · Cancer Cell International
38. Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV + Oropharyngeal Cancer
    Ari Joseph Rosenberg, Nishant Agrawal, Aditya Juloori, John Cursio, Zhen Gooi, Elizabeth A. Blair, Jeffrey Chin, Daniel Thomas Ginat, Olga Pasternak-Wise, Rifat Hasina et al. · 2024 · JAMA Oncology
39. Melanoma Treatment with Intratumoral Electroporation of Tavokinogene Telseplasmid (pIL-12, Tavokinogene Telseplasmid)
    David A. Canton, Shawna A. Shirley, Jocelyn H. Wright, Richard J. Connolly, Christoph Burkart, Anandaroop Mukhopadhyay, Chris Twitty, Kristen E Qattan, Jean S. Campbell, Mai Hope Le et al. · 2017 · Immunotherapy
40. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials
    Run‐Cong Nie, Fo‐Ping Chen, Shuqiang Yuan, Ying-Shan Luo, Shi Chen, Yongming Chen, Xiao‐Jiang Chen, Ying-Bo Chen, Yuanfang Li, Zhiwei Zhou · 2018 · European Journal of Cancer
41. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays
    David B. Chapel, Rachel Lauren Stewart, Larissa V. Furtado, Aliya Noor Husain, Thomas N Krausz, Georgios Deftereos · 2019 · Human Pathology
42. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
    Clint Tanner Allen, Sunmin Lee, Scott Michael Norberg, Damián Kovalovsky, Ye Hong, Paúl E. Clavijo, Siwen Hu‐Lieskovan, Richard Schlegel, Jeffrey Schlom, Julius Strauss et al. · 2019 · Journal for ImmunoTherapy of Cancer
43. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
    Pooja H. Rambhia, Barbara Reichert, Jeffrey F. Scott, Ashley N. Feneran, Jordan Kazakov, Kord S. Honda, Henry B. Koon, Meg R. Gerstenblith · 2019 · International Journal of Clinical Oncology
44. Exosomes in Head and Neck Squamous Cell Carcinoma
    Xiao Cheng, Fang Song, Yu Zheng, Jiong Lv, Qiang Feng Wang, Nong Xu · 2019 · Frontiers in Oncology
45. Who is who in oral cancer?
    Wei‐long Zhang, Shasha Wang, Haofan Wang, Ya-Jie Tang, Ya‐ling Tang, Xin‐hua Liang · 2019 · Experimental Cell Research
46. High PD‐L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta‐analysis of the literature
    Giuseppe Troiano, Vito Carlo Alberto Caponio, Khrystyna Zhurakivska, Claudia Arena, Giuseppe Pannone, Marco Mascitti, Andrea Santarelli, Lorenzo Lo Muzio · 2018 · Cell Proliferation
47. XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary
    Ryo Tamura, Kosuke Yoshihara, Hirofumi Nakaoka, Nozomi Yachida, Manako Yamaguchi, Kazuaki Suda, Tatsuya Ishiguro, Koji Nishino, Hiroshi Ichikawa, Keiichi Homma et al. · 2020 · Oncogene
48. Adenosine-producing regulatory B cells in head and neck cancer
    Sandra S. Jeske, Matthias Brand, Andreas Ziebart, Simon A. Laban, Johannes Doescher, Jens Greve, Edwin Kerry Jackson, Thomas Karl Hoffmann, Cornelia Brunner, Patrick Johannes Schuler · 2020 · Cancer Immunology Immunotherapy
49. Systemic treatment of advanced or recurrent biliary tract cancer
    Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li · 2020 · BioScience Trends
50. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study
    Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda et al. · 2020 · International Journal of Clinical Oncology
51. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer
    Meng Qi, Yun‐Xin Lu, Dan‐Yun Ruan, Kai Yu, Yan‐Xing Chen, Min Xiao, Yun Wang, Zexian Liu, Rui‐Hua Xu, Huai‐Qiang Ju et al. · 2021 · Molecular Therapy — Nucleic Acids
52. Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer
    Meytal Guller, Matthew E. Herberg, Neha Amin, Hosam H. Alkhatib, Christopher A. Maroun, Evan S. Wu, Hailey Allen, Ying Zheng, Christine Gail Gourin, Peter S. Vosler et al. · 2021 · Cancers
53. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
    Maura L. Gillison, George R. Blumenschein, Jérôme Fayette, Joël Guigay, Alexander Dimitrios Colevas, Lisa Francesca Licitra, Kevin Joseph Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even et al. · 2022 · The Oncologist
54. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges
    Trisha Michel Wise-Draper, Houda Bahig, Marion Tonneau, Vidhya Karivedu, Barbara Ann Burtness · 2022 · American Society of Clinical Oncology Educational Book
55. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
    Chieko Michikawa, Vancheswaran Gopalakrishnan, Amani M. Harrandah, Tatiana V. Karpinets, Rekha Rani Garg, Randy Aaron Chu, Yuk Pheel Park, Sasanka S. Chukkapallia, Nikhita Yadlapalli, Kelly Erikson et al. · 2022 · Neoplasia
56. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
    Wan‐Teck Lim, Hsiang‐Fong Kao, Lisda Suteja, Constance H. Li, Hong Sheng Quah, Daniel S.W. Tan, Sze Huey Tan, Eng-Huat Tan, Wan-Ling Tan, Justina Nadia Lee et al. · 2023 · Nature Communications
57. Clinical development of immuno-oncology therapeutics
    Jianxin Wang, Qi Chen, qiang Shan, Tingbo Liang, Patrick M. Forde, Lei Zheng · 2025 · Cancer Letters
58. Treatment Options for Hypopharyngeal Cancer
    Hans Edmund Eckel, Patrick James Bradley · 2019 · Advances in oto-rhino-laryngology
59. Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single‐institution outcomes
    James E. Bates, Alexandra N. De Leo, Christopher G. Morris, Robert J. Amdur, Roi Dagan · 2019 · Head & Neck
60. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care—A Systematic Review
    Evan Thomas Hall, Surbhi Singhal, James Charles Dickerson, Brooke Peterson Gabster, Hong-Nei Wong, Rebecca A. Aslakson, Lidia Schapira, Rebecca A. Aslakson, Katherine Ast, Thomas Carroll et al. · 2019 · Journal of Pain and Symptom Management
61. Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)
    Carol C. Cheung, Penny J. Barnes, Gilbert Bigras, Scott L. Boerner, JAGDISH W. BUTANY, Fiorella Calabrese, Christian Couture, Jean Deschênes, Hala M.T. El-Zimaity, Gábor Fischer et al. · 2019 · Applied immunohistochemistry & molecular morphology
62. The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Head and Neck Cancer
    Masahiro Nakayama, Masahiko Gosho, Masahiro Adachi, Rieko Ii, Shin Matsumoto, Hidetaka Miyamoto, Yuki Hirose, Bungo Nishimura, Shuho Tanaka, Tetsuro Wada et al. · 2020 · The Laryngoscope
63. Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
    Maria Togo, Takehiko Yokobori, Kimihiro Shimizu, Tadashi Handa, Kyoichi Kaira, Takaaki Sano, Mariko Tsukagoshi, Tetsuya Higuchi, Satoshi Yokoo, Ken Shirabe et al. · 2020 · British Journal of Cancer
64. CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients’ plasma as potential noninvasive biomarkers of disease activity
    Marie‐Nicole Theodoraki, Akihiro Matsumoto, Inga J. Beccard, Thomas Karl Hoffmann, Theresa L. Whiteside · 2020 · OncoImmunology
65. Therapeutic applications of the cancer immunoediting hypothesis
    Rupen R. Desai, Andrew T. Coxon, Gavin P. Dunn · 2021 · Seminars in Cancer Biology
66. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
    Marc Oliva, Douglas Brian Chepeha, Daniel Vilarim Araújo, J. Javier Díaz-Mejía, Peter Olson, Amy Prawira, Anna Spreafico, Scott Victor Bratman, Tina L. T. Shek, John R. de Almeida et al. · 2021 · Journal for ImmunoTherapy of Cancer
67. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
    Kazutomo Niwa, Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Takashi Saotome, Masashi Okazaki, Keisuke Yamazaki, Isaku Okamoto, Hideaki Hirai, Natsuki Saigusa et al. · 2020 · Scientific Reports
68. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
    Dante J. Merlino, Jennifer Maria Johnson, Madalina Tuluc, Stacey Gargano, Robert Stapp, Larry A. Harshyne, Benjamin E. Leiby, Adam Eugene Flanders, Ralph Zinner, Rita Susan Axelrod et al. · 2020 · Frontiers in Oncology
69. Analysis of the Prognosis and Therapeutic Value of the CXC Chemokine Family in Head and Neck Squamous Cell Carcinoma
    Yongchao Li, Tinghui Wu, Shujuan Gong, Hangzheng Zhou, Lufei Yu, Meiyan Liang, Ruijun Shi, Zhen-Hui Wu, Jinpei Zhang, Shuwei Li · 2021 · Frontiers in Oncology
70. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More
    Xuejin Ou, Qizhi Ma, Wei Yin, Xuelei Ma, Zhiyao He · 2021 · Frontiers in Cell and Developmental Biology
71. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
    Sixue Liu, Hannah M. Knochelmann, Shirley H. Lomeli, Aayoung Hong, Mary S. Richardson, Zhentao Yang, Raymond J. Lim, Yan Wang, Camelia Dumitras, Kostyantyn Krysan et al. · 2021 · Cell Reports Medicine
72. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma
    Kaikai Yi, Xiaoteng Cui, Xing Liu, Yunfei Wang, Jixing Zhao, Shixue Yang, Can Xu, Eryan Yang, Menglin Xiao, Biao Hong et al. · 2022 · Frontiers in Immunology
73. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
    Md. Mominur Rahman, Tapan Behl, Md. Rezaul Islam, Md. Rezaul Islam, Md. Rezaul Islam, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya, SIMONA GABRIELA BUNGAU · 2022 · Molecules
74. Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer
    Julie E. Bauman, Nabil F. Saba, Denise J. Roe, Jessica Ruth Bauman, John M. Kaczmar, Aarti Khushal Bhatia, Jameel Muzaffar, Ricklie Ann Julian, Steven Wang, Shethal Bearelly et al. · 2023 · Journal of Clinical Oncology
75. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update
    Hiroki Nagai, Manabu Muto · 2018 · International Journal of Clinical Oncology
76. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors
    Alice de Malet, Guillemette Antoni, Michael Collins, Émilie Soularue, Lysiane Marthey, Thibaut Vaysse, Clélia Coutzac, Nathalie Chaput, Christine Mateus, Caroline Robert et al. · 2018 · European Journal of Cancer
77. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
    Takeo Shibata, Benjamin J. Lieblong, Toshiyuki Sasagawa, Mayumi Nakagawa · 2019 · Cancer Treatment Reviews
78. Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors
    Ewelina Grywalska, Małgorzata Sobstyl, Lechoslaw T. Putowski, Jacek Roliński · 2019 · International Journal of Molecular Sciences
79. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
    Nicholas Gravbrot, Kacy Gilbert-Gard, Paras P Mehta, Yarah Ghotmi, Madhulika Banerjee, Christopher M. Mazis, Srinath Sundararajan · 2019 · Antibodies
80. Challenges in assessing solid tumor responses to immunotherapy
    Louis F. Chai, Ethan A. Prince, Venu Gopal Pillarisetty, Steven C. Katz · 2019 · Cancer Gene Therapy
81. Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers
    Sandra Ortiz‐Cuaran, Jebrane Bouaoud, Andy Karabajakian, Jérôme Fayette, Pierre Saintigny · 2021 · Frontiers in Oncology
82. Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana‐Farber Cancer Institute, 2011 to 2019
    Yuanming Xu, Natalie Wen, Stephen T. Sonis, Alessandro Villa · 2021 · Cancer
83. Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
    Takuma Matoba, Masaki Imai, Naganari Ohkura, Daisuke Kawakita, Kei Ijichi, Tatsuya Toyama, Akimichi Morita, Shingo Murakami, Shimon Sakaguchi, Sayuri Yamazaki · 2018 · International Journal of Cancer
84. Immunotherapy for squamous cell carcinoma of the head and neck
    Tomoya Yokota, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano et al. · 2020 · Japanese Journal of Clinical Oncology
85. Total Laryngectomy—Still Cutting-Edge?
    Thomas Karl Hoffmann · 2021 · Cancers
86. Precision drugging of the MAPK pathway in head and neck cancer
    Hoi-Lam Ngan, Chun Ho Law, Yannie Chung Yan Choi, Jenny Yu-Sum Chan, Vivian Wai Yan Lui · 2022 · npj Genomic Medicine
87. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma
    Kohei Okuyama, Tomofumi Naruse, Souichi Yanamoto · 2023 · Journal of Experimental & Clinical Cancer Research
88. Effects of the Community-Based Wellspring Cancer Exercise Program on Functional and Psychosocial Outcomes in Cancer Survivors
    Daniel Santa Mina, Darren Au, Jennifer Brunet, Jennifer Michelle Jones, GEORGE A. TOMLINSON, Nathan Taback, D. Field, Antonia Berlingeri, H. Bradley, Doris Howell · 2017 · Current Oncology
89. Immunotherapy in the Asiatic population: any differences from Caucasian population?
    Lun-Xi Peng, Yi-Long Lung Cancer Wu · 2018 · Journal of Thoracic Disease
90. New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
    Michael A. Curran, Bonnie S. Glisson · 2018 · Annual Review of Medicine
91. Assessment of tumor mutation burden calculation from gene panel sequencing data
    Zhenwu Xu, Jiawei Dai, Dandan Wang, Hui Juan Lu, Heng Dai, Hao Ye, Jianlei Gu, Shengjia Chen, Bingding Huang · 2019 · OncoTargets and Therapy
92. ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to cisplatin
    Brandon C. Leonard, Eliot D. Lee, Neil E. Bhola, Hua Li, Kristian K. Sogaard, Christopher J. Bakkenist, Jennifer Rubin Grandis, Daniel E. Johnson · 2019 · Oral Oncology
93. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
    Galina Lagos, Benjamin Izar, Naiyer A. Rizvi · 2020 · American Society of Clinical Oncology Educational Book
94. Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
    Annie Wai Yeeng Chai, Pei San Yee, Stacey Price, Shi Mun Yee, Hui Mei Lee, Vivian KH Tiong, Emanuel Gonçalves, Fiona M. Behan, Jess Bateson, James G. R. Gilbert et al. · 2020 · eLife
95. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts
    Nora Wuerdemann, Katharina Pütz, Hans Nikolaus Caspar Eckel, Rishabh A. Jain, Claus Wittekindt, Christian Ulrich Huebbers, Shachi Jenny Sharma, Christine Langer, Stefan Gattenlöhner, Reinhard Büttner et al. · 2020 · International Journal of Molecular Sciences
96. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
    C. Quinn, L. Garrison, A. Pownell, M. Atkins, G. de Pouvourville, K. Harrington, P. Ascierto, P. McEwan, S. Wagner, J. Borrill et al. · 2020 · Journal for ImmunoTherapy of Cancer
97. Immunotherapy in older patients with cancer
    Clémence Granier, Alain Gey, Stéphane Roncelin, Laurence Weiss, Éléna Paillaud, Éric Tartour · 2020 · Biomedical Journal
98. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
    Chenhang Yu, Qiang Li, Yu Zhang, Zhifa Wen, Heng Dong, Yongbin Mou · 2022 · Frontiers in Cell and Developmental Biology
99. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma
    Anna Lee, Robbie Woods, Amgad Mahfouz, Sarin Kitpanit, Olivia Cartano, Nader Mohamed, Irini Youssef, Kathryn E. Marqueen, Kevin Sine, Dennis W. Mah et al. · 2023 · JAMA Network Open
100. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
     G. Hanna, D. Adkins, P. Zolkind, R. Uppaluri · 2017 · Oral Oncology